Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Stereotactic Ablative Body Radiotherapy (SABR) Combined with Immunotherapy (L19-IL2) in Stage IV NSCLC Patients, ImmunoSABR: a Multicentre, Randomised Controlled Open-label Phase II Trial

Next Previous
Search
Trial Profile

Stereotactic Ablative Body Radiotherapy (SABR) Combined with Immunotherapy (L19-IL2) in Stage IV NSCLC Patients, ImmunoSABR: a Multicentre, Randomised Controlled Open-label Phase II Trial

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bifikafusp alfa (Primary) ; Antineoplastics
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms IMMUNOSABR2

Most Recent Events

  • 30 Jan 2025 Status changed from active, no longer recruiting to discontinued. (This trial is not transitioning to the Clinical Trial Regulation (CTR) EU No 536/2014.)
  • 16 May 2024 Planned End Date changed from 1 Dec 2024 to 31 Jan 2025.
  • 16 May 2024 Planned primary completion date changed from 1 Dec 2024 to 31 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top